Percheron Therapeutics Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los beneficios de Percheron Therapeutics disminuyan en un 27.3% al año, mientras que se espera que sus ingresos anuales crezcan en un 14.8% al año. Se prevé que el BPA disminuya en un 27% por año. Se espera que la rentabilidad financiera sea de -84.2% en 3 años.

Información clave

-32.3%

Tasa de crecimiento de los beneficios

-28.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	33.1%
Tasa de crecimiento de los ingresos	14.6%
Rentabilidad financiera futura	-12.5%
Cobertura de analistas	Low
Última actualización	31 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

Previsiones de crecimiento de beneficios e ingresos

ASX:PER - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	4	-23	N/A	-14	1
6/30/2025	5	-31	N/A	-15	1
6/30/2024	4	-13	N/A	-16	1
12/31/2023	2	-11	-10	-10	N/A
9/30/2023	2	-11	-9	-9	N/A
6/30/2023	2	-11	-8	-8	N/A
3/31/2023	2	-10	-7	-7	N/A
12/31/2022	2	-8	-7	-7	N/A
9/30/2022	2	-7	-7	-7	N/A
6/30/2022	2	-6	-8	-8	N/A
3/31/2022	1	-7	-8	-8	N/A
12/31/2021	1	-9	-8	-8	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-8	-6	-6	N/A
3/31/2021	1	-6	-5	-5	N/A
12/31/2020	1	-4	-4	-4	N/A
9/30/2020	1	-5	-4	-4	N/A
6/30/2020	1	-6	-4	-4	N/A
3/31/2020	1	-6	-3	-3	N/A
12/31/2019	1	-6	-3	-3	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	0	-3	-3	-3	N/A
12/31/2018	0	-3	-3	-3	N/A
9/30/2018	0	-3	-3	-3	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	-2	-2	N/A
12/31/2017	0	-2	-3	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	2	-2	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	4	1	N/A	0	N/A
9/30/2015	5	1	N/A	1	N/A
6/30/2015	5	1	N/A	1	N/A
3/31/2015	3	-1	N/A	-1	N/A
12/31/2014	1	-3	N/A	-3	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	1	-3	N/A	-2	N/A
9/30/2013	1	-3	N/A	-2	N/A
6/30/2013	1	-2	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PER siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PER siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PER siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (14.8% al año) de PER crezcan más rápidamente que los del mercado Australian (4.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 14.8% al año) de PER crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: PER se prevé que no sea rentable en 3 años.

Percheron Therapeutics Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

Consensus revenue estimates increase by 71%

Price target increased to AU$0.31

Price target increased to AU$0.31

Consensus forecasts updated

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento